December 10th & 11th, 2026
15th edition
MARSEILLE, FR

What to ensure before the creation of a viable spinout opportunity?

What to ensure before the creation of a viable spinout opportunity?

What does viable mean for TTOs, and do we have the same definition everywhere? On which grounds are TTOs advising to create a spin-off rather than out-licensing the IP or a contract-based R&D collaboration? Which are the benefits, limits, constraints and indication of the spin-out model? What are the key factors to create a well-conceived spin-off company, how to exploit and maximise the value creation?

Jürgen Walkenhorst

Managing Director
Life Science Nord

Rafaela Kunz

Open Innovation Consultant, Biotechnologist & IP Expert
InseaConsulting

Pierre D’Epenoux

CEO
Imcheck Therapeutics

Anna Bialek Jaworska

Professor & Economist
University of Warsaw
Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.